IMBdx

Company Profile

Sector

Healthcare

Industry

Diagnostics & Research

Employees

N/A

Website

www.imbdx.com

Country

South Korea

Exchange

KOSDAQ

Founded 2018

IMB Dx provides liquid biopsy platform in South Korea. It offers AlphaLiquid Platform that provides circulation-tumor DNA-based precision diagnostics solutions across various stages of cancer for patients, survivors, and individuals.

Its portfolio also includes AlphaLiquid HRR for diagnostics of targeted therapies, utilizing liquid biopsy profiling technology, and AlphaLiquid 100 test, a tool that enables the detection of biomarkers across 118 cancer-related genes through one blood test

CancerDetect, a liquid biopsy platform for the early detection of cancer recurrence post-surgery; and CancerFind, a blood-based test for various cancer early detection. Founded in 2018, IMB Dx is based in Seoul, South Korea.

Key Stats

52-Week Range

₩2550.00₩12990.00

Beta0.46

Trailing P/EN/A

Forward P/EN/A

Trailing EPSN/A

Avg Volume

Earnings & Analyst

Next EarningsN/A

EPS EstimateN/A

Target Mean PriceN/A

RecommendationNone

Recommendation MeanN/A

Recent SEC Filings

SEC filings for this ticker are not available yet.